Search for stocks /

Tega Industries:Mining Consumables. ₹1,100 Cr Order Book. $1.4B Molycop Acquisition. Margin Squeeze. Timing Issues. Deal Closing by Mar 31?

Tega Industries Q3 FY26 | EduInvesting
Q3 FY26 Results · Quarterly (Dec 2025)

Tega Industries:
Mining Consumables. ₹1,100 Cr Order Book. $1.4B Molycop Acquisition. Margin Squeeze. Timing Issues. Deal Closing by Mar 31?

World’s second-largest mill liner maker trying to become the world’s largest by acquiring a $1.455 billion grinding media company. Q3 looked rough on paper. Management says it’s just accounting theatrics from acquisition costs. Let’s find out who’s lying.

Market Cap₹13,457 Cr
CMP₹1,788
P/E Ratio66.6x
ROCE17.8%
Div Yield0.11%

The Mill Liner That Wants To Grind Mountains. And Buy Molycop Doing It.

  • 52-Week High / Low₹2,130 / ₹1,200
  • Q3 FY26 Revenue₹404 Cr
  • Q3 FY26 PAT₹19.7 Cr
  • Q3 EPS₹2.62
  • Annualised EPS (Q3×4)₹10.48
  • Book Value₹196
  • Price to Book9.10x
  • Debt / Equity0.21x
  • Interest Coverage11.5x
  • 9M Revenue₹1,210 Cr
Auditor’s Opening Note: Tega delivered 9M FY26 revenue of ₹1,210.3 cr (+6% YoY) and ₹216.1 cr EBITDA (18% margin, down from 20% last year — thanks, Molycop deal costs!). But here’s the twist: management claims that excluding one-off acquisition-related professional fees and new labour code charges, EBITDA margins would be above 20%. Q3 itself was a dumpster fire with ₹19.7 cr PAT (down 63.7% YoY). The stock has returned -10.5% in six months. Meanwhile, Tega has upsized its stake to 84% in Molycop and expects the $1.455 billion deal to close by March 31, 2026. This is either the greatest value trap ever created, or a generational acquisition about to pay off. Let’s investigate.

Welcome to the Grindstone Wars: When Mill Liners Attack

Tega Industries manufactures polymer-based mill liners. No, not the beer. Mill liners are rubber-ish consumable wear components that line the insides of grinding mills used in mineral processing. Copper mines. Gold mines. Anything you dig out of the earth that needs crushing and grinding — Tega’s products go into the machine doing the crushing.

Since 1976, they’ve quietly dominated this niche. Second-largest globally by revenue in polymer-based mill liners. 75% of orders are repeat orders (sticky, recurring, beautiful). Global footprint spanning 70+ countries. Only 10-15% of revenue comes from India — this is a global consumables business with near-perfect pricing power because switching costs are non-zero and customers care about uptime more than price.

Then in November 2025, they got ambitious. Tega announced they’d acquire Molycop — the world’s largest manufacturer of grinding media (those steel balls that do the actual grinding inside mills) — for $1.455 billion enterprise value. Enterprise value. With debt inside. This wasn’t a small bolt-on. This was “we’re going to become the global comminution circuit leader” energy.

The deal structure: Tega owns 84% (~$359 million equity stake), Apollo Funds owns 16% (and is infusing $270 million in perpetual preference shares to optimize Molycop’s capital structure). Financing: ₹1,713 crore raised via preferential share issue in November 2025 at ₹1,994 per share. Plus ₹1,500 crore debt. Plus ₹3,517 crore in OCRPs (Optionally Convertible Redeemable Preference Shares). Plus internal accruals. Deal closing: expected by March 31, 2026, pending antitrust approvals in 12 jurisdictions.

So now Tega is a company in transition: smaller, focused business (the mills and consumables) plus a pending mega-acquisition that’s already diluting EPS because every quarter brings fresh “transaction costs.” Q3 was ugly. But management keeps saying the underlying business is fine. Let’s figure out if they’re right or just really good at spin.

Concall Highlight (Feb 2026): CFO on margin compression: “Excluding one-off items, our EBITDA margins would be above the 20% threshold.” Translation: the reported numbers look terrible, but the “real” business is fine. Sure. Show us the numbers without the magic wand.

Rubber Liners. Steel Balls. Mining Suffering. Tega Profits.

The business splits into two segments: Consumables (84% of revenue pre-acquisition) and Equipment (16%).

Consumables: Mill liners (the rubber part that prevents ore from sticking to the mill), wear-resistant components, conveyor components, screens, trommels, hydrocyclones. All of these are critical-to-operate items. A mine’s grinding mill breaks down because the liner wears out, and the mine loses millions per hour of downtime. So they buy Tega’s premium products at premium prices. 75% of Tega’s revenue comes from repeat orders because once you put Tega in your mill, switching is pain. The customer knows the fit, the performance, the exact delivery timeline. Why risk a different supplier?

Equipment: Tega acquired Tega McNally Minerals Ltd (TMML) in Feb 2023, which manufactures grinding mills, screens, trommels, material handling, and processing equipment. Global market size for equipment: ~$28 billion annually. Tega’s trying to integrate equipment sales with consumables — sell the mill + the liners that go into it + the ongoing spares. Lock in the customer for life.

Geography: 85-90% of revenue from exports. Gold + copper mining drives 75-77% of demand. When copper and gold prices go up, more marginal mines reactivate, ore throughput increases, and Tega ships more liners. Raw material exposure: ~50% of base chemical inputs are imported (though management says they hedge and have local sourcing).

Repeat Orders %75%Of Annual Revenue
Global Market Rank2ndMill Liners (By Revenue)
Countries Present70+Global Footprint
Export Revenue %85-90%Global Exposure
Working Capital Trap: Tega’s cash conversion cycle is ~212 days (as of Mar 2025). Why? Exports involve 60-90 days transit, plus 30-60 days of customer credit terms. So you manufacture in month 1, ship in month 2, and get paid in month 4. Meanwhile, you’ve already paid your suppliers in month 1. This is why GCAs (Gross Current Assets) are at ~219 days. The Molycop acquisition will likely worsen this because you’re integrating a company with similar working capital characteristics.
💬 Question for you: If your company’s tied-up cash is 7 months of sales, how comfortable are you acquiring another company on debt? Drop your thoughts.

Q3 Results: The Plot Thickens (Very Badly)

Result Type: Quarterly Results  |  Q3 FY26 EPS: ₹2.62  |  Annualised EPS (Q3×4): ₹10.48  |  9M FY26 Revenue: ₹1,210.3 Cr

Source table
Metric (₹ Cr) Q3 FY26
Dec 2025
Q3 FY25
Dec 2024
Q2 FY26
Sep 2025
YoY % QoQ %
Revenue404409405-1.36%-0.2%
Operating Profit469169-49.5%-33.3%
OPM %11%22%17%-1100 bps-600 bps
PAT19.75445-63.7%-56.2%
EPS (₹)2.628.156.75-67.8%-61.2%
💥 OPM Crashed 1,100 basis points YoY (22% → 11%): This is not a typo. Operating margin went from a healthy 22% to an embarrassing 11% in one year. But management’s explanation is compelling: 9M gross margin actually improved to 59% (up from 57% YoY) on product/regional mix and high-margin order execution. The operating margin collapse is because of operating expense and depreciation spikes tied to acquisition costs. Q3 specifically saw PAT drop 63.7% YoY even as revenue was flat. The culprit? Non-operating items, depreciation charges, and that blasted labour code benefit charge (~₹6 crore at group level).
What Actually Happened: 9M revenue grew +6% to ₹1,210.3 cr. EBITDA was ₹216.1 cr (18% margin). Management’s claim: “Excluding one-off acquisition-related professional fees and labour code charges of ~₹45-50 cr in Other Expenses, and excluding the ~₹6 cr labour code charge, normalized EBITDA would be ₹271-276 cr at ~22-23% margin.” If true, that’s a very different story. If false, it’s a textbook case of excuses.

The Tale of Two Businesses (And Only One Is Growing)

Consumables (84% of 9M revenue, ₹1,017 cr): Growth is soft at ~6% YoY, but management frames this as a timing issue, not a market issue. Quote from MD: “Sustainable spares (repeat orders) is back very strong, but new customer conversions experienced a lag.” Translation: you’ve got repeat business rolling in, but converting *new* customers has stalled. CFO added: “There is no market loss per se — only about a volume shift from this quarter to subsequent quarters.” So orders are delayed by “a quarter or two,” not cancelled. The company guided full-year consumables growth at ~8% (vs earlier higher aspirations). Gross margin on consumables is typically 57-60%, with EBITDA margin of 22-23%. They pass on raw material inflation via contractual mechanisms with a quarter lag.

Equipment (16% of 9M revenue, ₹183 cr): This is the growth engine. 9M equipment revenue: ₹182.6 cr, +34% YoY. But Q3 equipment revenue was ₹47.5 cr vs ₹54.7 cr YoY (decline of -13% QoQ). Why? Project shipment timing. Equipment deals are lumpy by nature. Q3 was weak, but management says the backlog is “strong” and Q3 spillover will ship in Q4. Gross margin on equipment: 40-45%. EBITDA margin: 13-14% (excluding unusual items, but caveated for “quarter-to-quarter lumpiness”). Equipment is now PBT-positive YTD vs marginally negative last year — so progress on profitability.

The Real Question: Equipment is meant to be the long-term growth story, but it’s lumpy and lower-margin than consumables. Molycop acquisition will add a *new* third segment (grinding media), which will be higher volume, but also higher capital-intensive. The synergy story is: sell Tega’s distribution to Molycop customers + Molycop’s distribution to Tega customers. But first, you have to integrate two complex international manufacturing bases. That’s a 2-3 year play, not a 6-month miracle.

What’s This Mining Play Worth? (Spoiler: Not Clear)

Method 1: P/E Based

9M FY26 EPS (annualized): ~₹10.48 (based on Q3×4). Industry peers for capital goods / industrial products trade at P/E of 28-50x on average. Tega at 66.6x P/E is expensive. But if Molycop closes and accretion kicks in, normalized EPS could be ₹12-14 by FY27. Fair P/E band (assuming post-Molycop): 35x–50x.

Range: ₹420 – ₹700 (based on FY27 est. EPS of ₹12-14)

Method 2: EV/EBITDA Based

TTM (trailing twelve months) EBITDA at standalone Tega: ~₹321 cr. Current EV: ~₹13,642 cr → EV/EBITDA = 42.5x. This is stratospheric for a consumables business. Post-Molycop, combined EBITDA (at $217 million per CRISIL rating, ~₹1,900 cr consolidated) would be ~₹2,221 cr at group level. If group EV normalizes to 20x–25x EBITDA, range would be ₹44,420–55,525 cr. Per share (at ~7.51 crore shares): ₹591–739.

Range: ₹550 – ₹750 (post-Molycop)

Method 3: DCF Based

Standalone Tega FCF: ~₹195 cr (CY25 OCF). Assume 5% growth (conservative, given order timing and conversion delays). Terminal growth: 3%. WACC: 10% (high leverage post-Molycop). Standalone PV of FCF over 5 years: ~₹750 cr. Terminal value at 3% perpetuity: ~₹6,500 cr. Total EV: ~₹7,250 cr. This values just the current Tega business at ₹966 per share. Molycop’s contribution post-integration adds optionality worth ₹300-400 per share (conservatively).

→ Standalone Tega: ~₹1,000/share
→ Molycop synergy optionality: +₹350-450/share
→ Total valuation: ~₹1,350-1,450/share (ONLY if deal closes and synergies materialize)

Range: ₹1,200 – ₹1,500 (post-deal closure)

Fair Min: ₹1,100 CMP: ₹1,788  |  Upside Potential (if deal closes): ₹1,200–1,500 Fair Max: ₹1,800
CMP ₹1,788 DCF Range ₹1,200–1,500
⚠️ EduInvesting Fair Value Range: ₹1,100 – ₹1,800. Current price ₹1,788 sits at the upper end of this range, implying the market is already pricing in some Molycop synergy assumptions. This fair value is heavily contingent on (1) Molycop deal closing by March 31, 2026, (2) antitrust approvals in 12 jurisdictions materializing, and (3) the company successfully integrating two complex global operations. This fair value range is for educational purposes only and is not investment advice. Please consult a SEBI-registered investment advisor before making any financial decision.

$1.455 Billion Bet. 84% Stake. March 31 Closing Target. Antitrust in 12 Jurisdictions.

🚀 The Deal: By The Numbers

Announced: November 29, 2025. Structure: Joint venture with Apollo Funds. Tega invests ~$359 million (equity) for 84% stake (later upsized to 84.2%). Apollo invests $109 million (16% stake) + $270 million in perpetual preference shares to optimize Molycop’s capital structure. Enterprise Value: $1.455 billion for 100% of Molycop. Financing by Tega: ₹1,713 crore raised via preferential share issue (Nov 28, 2025, at ₹1,994/share, ~8.59 crore shares allotted) + ₹1,500 crore debt approved + ₹3,517 crore in OCRPs (20-year tenure). Expected Close: March 31, 2026 (with acknowledgment of possible spillover). Molycop Profile: World’s leading grinding media manufacturer (those steel balls/cylinders used in mills). Revenue: ~$460 million annually. EBITDA: ~$217 million (47% margin). Global operations in US, Australia, South Africa, Chile, Mexico.

✅ Synergy Story

  • • Complementary products: Tega liners + Molycop media = complete comminution circuit
  • • Combined revenue (at pro-forma): ~$1.7 billion (Tega ₹1,700 cr + Molycop $460 mn)
  • • 23 global manufacturing sites post-deal (closer to customers in all geographies)
  • • Cross-sell to Molycop’s customer base (estimated 50+ mining customers globally)
  • • Cost synergies: procurement, manufacturing footprint optimization

⚠️ Execution Risks

  • • Antitrust approvals pending in 12 jurisdictions (US, Canada, LATAM, Australia, Saudi Arabia, EU)
  • • Filings completed by late January 2026; reviews ongoing
  • • FDI filing in Spain pending
  • • Deal closing delay could spillover past Q4 FY26
  • • Integration complexity: two large global operations with different supply chains
Financing Risk Alert: Tega has upsized its equity raise to ₹1,713 crore (from earlier ₹1,500 crore guidance) and now holds ₹4,300+ crore in external funding instruments (debt + OCRPS). Post-deal, debt/EBITDA at consolidated level expected to be >4x initially, improving over time as synergies kick in (per CRISIL rating, continued on Watch Developing). CFO assured that “financial closure is achieved under current resources,” but refinancing risk on Molycop’s existing debt (~$450 million) at higher rates post-deal could pressure returns. Watch for this very closely in FY27.
💬 Critical question: Do you trust management to execute a $1.4B integration while also managing a business with 212-day cash conversion cycle? Or is this leverage play going to blow up?

Assets Growing. Debt Surging. Equity Getting Diluted.

Source table
Item (₹ Cr) Sep 2025 Mar 2025 Mar 2024 Mar 2023
Total Assets2,1502,0891,8851,629
Net Worth (Reserves+Equity)1,4761,3971,1921,049
Borrowings305330308361
Other Liabilities369363385219
Total Liabilities2,1502,0891,8851,629
💸 Borrowings at ₹305 Cr (as of Sep 2025): Down from ₹330 cr in Mar 2025. But this is *before* the Molycop debt hits the books. Post-deal, expect consolidated debt of $450+ million from Molycop alone, plus ₹1,500 crore fresh Tega borrowing, plus the ₹3,517 crore OCRPS. You’re looking at a debt/equity ratio north of 0.8x–1.0x post-deal. Liquidity is currently strong at ₹412 crore (cash + marketable securities as of Sep 2025), but that burns quickly post-acquisition.
📈 Net Worth Up ₹79 Cr in 6 months: From ₹1,318 cr (Mar 2025) to ₹1,397 cr (Sep 2025). But check the fine print: ₹1,713 crore in equity just got raised (Nov 2025). So net worth will spike post-allotment, but so will share count (now ~7.6 crore from ~7.5 crore). Book value per share: ₹196 (before new equity dilution). Post-equity raise, expect book value per share to drop to ~₹150-155.
🧮 Working Capital Cycle = 212 Days: This is your achilles heel. 112 days of receivables + 217 days of inventory – 116 days of payables = 212 days of cash trapped in operations. Post-Molycop integration, if you don’t rationalize supplier payment terms and customer collection timelines, you’ll bleed working capital every single quarter. Management’s cautious on this point.

Operating CF Is Fine. But Transaction Costs Are Eating Everything.

Source table
Cash Flow (₹ Cr)Mar 2025Mar 2024Mar 2023
Operating CF+195+252+179
Investing CF-129-96-235
Financing CF-38-115+63
Net Cash Flow+28+41+6
✅ ₹195 Cr Operating CFSteady and stable. Tega generates cash. The underlying business is not broken. But this OCF has to service capex, debt interest, and now cover acquisition-related working capital drains.
⚠ -₹129 Cr Investing CFCapex + equity in subsidiaries (Chile plant coming online in Q2 FY27 with ₹250 cr capex underway). This is structural. Capex will increase further post-Molycop as you rationalize manufacturing footprints.
⚠ Acquisition Costs Hit OPMEvery quarter brings fresh “milestone-linked” costs and refinancing fees (management’s words). These sit at the Singapore acquisition entity and don’t hit the reported Tega consumables segment. But they hit the consolidated P&L. This is why Q3 margins looked so terrible.
📊 FY25 OutlookManagement projects 280+ crore OCF in medium term, with 50-60 crore yearly loan obligation. Headroom exists. But post-Molycop, if working capital gets tight, you’ll need to refinance Molycop’s existing debt. Watch this.

ROCE Is Mediocre. ROE Is Weak. P/E Is Stratospheric.

ROCE17.8%Industry: 16–20%
ROE15.5%Below Cost of Equity
P/E66.6xIndustry Avg: 28–35x
Debt/Equity0.21xAbout to 0.8x+ post-deal
Interest Coverage11.5xComfortable Now
P/B9.10xRich Valuation
PBT Margin8%Down from 15% YoY
Dividend Yield0.11%Almost Non-Existent
The Valuation Trap: At 66.6x P/E, you’re pricing in perfect Molycop integration, zero execution risk, and normalized earnings of ₹26+ per share by FY27. That’s a heroic assumption. The stock has returned +38.5% in one year and +40.5% over three years — but that’s pre-Molycop bump. Post announcement, it’s up another 30%. The market is treating this like a sure thing. It’s not. Antitrust risk alone could derail the deal. Integration risk could drag returns for 2-3 years.

Revenue Growing. But Margins Crumbling Like Cookies in Milk.

Source table
Metric (₹ Cr)Mar 2025Mar 2024Mar 2023Mar 2022
Revenue1,6391,4931,214952
Operating Profit341317271184
OPM %21%21%22%19%
PAT200194184117
EPS (₹)30.0829.1427.7317.63
Revenue CAGR (3yr)+13.8%
PAT CAGR (3yr)+1.8%
OPM 3-Yr Avg21%Stable Until Now

Revenue grew 13.8% CAGR over 3 years, but PAT grew only 1.8% CAGR. Translation: top-line growth was eaten by depreciation (TMML acquisition), interest (debt service), and now acquisition-related charges. This is why EPS growth has been anaemic. Once Molycop synergies kick in (if they do), the leverage will flip in your favour.

Tega vs. The Competition (Mostly Losing)

Honeywell AutoP/E 52.8xROCE 18.4%₹27,091 Cr
Kaynes TechP/E 63.6xROCE 14.3%₹24,815 Cr
Jyoti CNC AutoP/E 48.6xROCE 24.4%₹17,215 Cr
Aditya InfotechP/E 74.7xROCE 19.5%₹18,956 Cr
Source table
CompanyLatest Revenue (₹ Cr)Latest PAT (₹ Cr)P/EROCE %ROE %
Tega Industries1,70120266.6x17.8%15.5%
Honeywell Auto4,61651352.8x18.4%13.7%
Kaynes Tech3,36839063.6x14.3%10.7%
Jyoti CNC Auto2,07035448.6x24.4%21.2%
Aditya Infotech3,77625474.7x19.5%20.9%

Tega’s P/E of 66.6x is pricey but not the worst in this peer set. Aditya Infotech is at 74.7x. But Aditya has 20.9% ROE vs Tega’s 15.5%. Jyoti CNC has a 24.4% ROCE vs Tega’s 17.8%. The peers earning higher returns trade at similar or lower multiples. That’s the red flag.

Promoters Sold. Then Bought Back. Now at 67.27%.

Shareholding Pattern (As of Dec 2025)

  • Promoters (Mohanka Family)67.27%
  • DIIs (incl. mutual funds, insurance)18.63%
  • Public12.63%
  • FIIs1.48%

Promoter pledging: 0.00%. No collateral risk. Shareholders count: 56,174 (up from 50k+ base).

Promoter Story

The Mohanka family founded Tega in 1976. Madan Mohan Mohanka (patriarch, ~7.32%) and his son Manish Mohanka (~9.69%) are the lead promoters. Family holds through Nihal Fiscal Services Pvt Ltd (49.71%). The family *diluted itself* significantly for the Molycop acquisition — promoter holding dropped from 74.8% (Dec 2024) to 67.27% (Dec 2025) due to the preferential share allotment. This tells you the deal is real, not a rumor. Promoters ate dilution rather than dilute existing shareholders excessively. That’s integrity (or financial tightness, depending on your view).

DII Ownership Observation: Tata Mutual Fund owns 5.57% (via Tata Small Cap Fund). HDFC BAs (Balanced Advantage Fund) owns 3.35%. SBI Magnum Mid Cap owns 2.24%. These are quality fund holders. The fact that they’re still in the stock post-Molycop announcement suggests institutional confidence in the long-term thesis.

CRISIL Put Them On Watch. Here’s Why That Matters.

✅ The Good News

  • ✓ Clean audit history — no material qualifications
  • ✓ Board has >50% independent directors
  • ✓ Investor grievance mechanism in place
  • ✓ ESG commitment (7.5% reduction in CO₂ emissions in FY24)
  • ✓ Chile capex execution on track (commercial production Q2 FY27)
  • ✓ Zero promoter pledge — family’s capital is fully at risk

⚠️ Watch List (CRISIL-Flagged)

  • ⚠ Credit rating on “Watch Developing” (as of Dec 18, 2025)
  • ⚠ Debt/EBITDA expected to exceed 4x post-Molycop (from current 0.18x)
  • ⚠ Integration execution risk (two large global operations)
  • ⚠ Working capital cycle of 212 days — post-deal integration could worsen
  • ⚠ Antitrust approval dependency in 12 jurisdictions
  • ⚠ Refinancing risk on Molycop’s $450M+ debt at higher rates
CRISIL Verdict (Dec 18, 2025): “Ratings continue on AA-/Watch Developing (Long-Term) and A1+/Watch Developing (Short-Term).” Translation: bank facilities are rated, but the rating agency is watching to see if the deal closes and synergies materialize. If deal closes successfully and leverage comes down to 2.5x–3.0x within 18 months, watch will be resolved upward. If execution stumbles, downgrade incoming.

The Comminution Circuit Wars (And Why Tega Just Went All-In)

🏆 Why Molycop? The Math.

Grinding media (Molycop’s domain) is 50%+ of the comminution circuit market. Grinding liners (Tega’s domain) is 30-40%. By owning both, you can offer an integrated solution to 75%+ of a mine’s comminution capex. Lock in the customer. Recurring spares follow. Molycop’s $217 million EBITDA (~47% margin) is double Tega’s consumables margin. That’s a juicy profit pool. Post-acquisition, combined EBITDA could be ₹2,200+ crore at consolidated level, with margin expansion from economies of scale and elimination of procurement redundancy.

💰 The Mining Cycle: Tailwind or Headwind?

Copper demand forecast: +4% CAGR to 2030 (per management’s cited “independent expert assessments”). Gold production expected similar. But here’s the catch: commodity prices are cyclical. Gold + copper have been strong, but geopolitical risk (Middle East, China), US Fed rate stance, and energy prices drive volatility. Management noted that 75-77% of revenues depend on gold + copper mining activity. When prices dip, throughput falls, and Tega’s shipments fall. This is not a defensive business.

⚡ The Competition: Are They Sleeping?

Molycop’s competitors in grinding media include Magotteaux (Belgium-based), Fonda Tondelli (Italy), and a few regional players. Molycop is the clear leader. Tega’s mill liner competitors include Ludowici (Germany), Trelleborg (Sweden), FLS Smith (Denmark), and Chinese makers. Tega is #2 globally, but brand moat is strong (customers are sticky). Post-deal, the combined entity will be hard to compete against in the “full comminution circuit” category. But it’ll also attract antitrust scrutiny — which is why 12 jurisdictions are reviewing this deal.

🔴 The Macro Wild Card: Transition to EVs & Decarbonization

Mining is energy-intensive and is facing regulatory pressure to reduce carbon. However, mine tonnage is expected to grow to support EV battery metal demand (copper, lithium, cobalt). So mining *volume* might stay resilient, but *margins* could compress if carbon pricing kicks in. Tega is exposed to mining volumes but not directly to carbon regulation (yet). Watch this 5-10 year tail risk.

Geographic breakdown: Tega operates in 70+ countries. US (~25-30% of sales), Australia (~15-20%), LATAM (~20-25%), Europe (~15%), Rest of World (~15-20%). Molycop has strengths in US, Australia, and LATAM. Post-deal, you’ll have geographic redundancy but also geographic diversification. That’s a net positive for risk management.

💬 Here’s the real question: Do you believe in “comminution circuit integration” as a durable competitive advantage? Or is this just Tega trying to make a splash and hope synergies follow? Drop your view!

The Grindstone’s Moment of Truth

⚖️

Tega Industries is at an inflection point. The standalone business is solid — 17.8% ROCE, consistent 20-21% operating margins, sticky repeat-order revenue from global mining customers. But the stock price (₹1,788) is pricing in a near-perfect execution of a $1.4 billion acquisition. That’s a heroic bet.

The Bull Case: Molycop deal closes by March 31, 2026. Antitrust approvals come through. Synergies begin flowing within 12 months. Combined EBITDA reaches ₹2,200+ crore by FY27. Leverage comes down to 2.5x by FY28. EPS accretion to ₹35-40 by FY27. Stock re-rates to 40x-50x on higher growth profile. Upside to ₹1,400–1,600 from current ₹1,788 (wait, that’s downside 😅). No, the real upside is if EPS grows to ₹40 at 50x P/E → ₹2,000+. But that assumes *perfect* integration over 24 months.

The Bear Case: Antitrust hiccup delays deal past Q4 FY26. Financing costs spike post-deal. Working capital pressure during integration. Synergies take 3-4 years to materialize instead of 12-18 months. Leverage stays elevated at 3.5x+. Interest costs erode profitability. EPS growth stalls at ₹12-15 for the next 3 years. Stock de-rates to 40x-45x on execution disappointment. Downside to ₹480-675. The stock is vulnerable if any single domino falls.

The Historical Context: Tega has executed acquisitions before (TMML in Feb 2023, Losugen in 2011, Chilean assets in 2011). But Molycop is 20x the size of anything they’ve bought before. Management’s first mega-deal. Integration complexity is substantially higher.

Baseline Expectation: Deal closes in Q4 FY26 (late March 2026, not early). Synergies flow slowly. EPS accretion is ₹2-3 per share in FY27 (vs ₹10+ management’s implied expectations). Market reprices from 66.6x to 45x-50x as execution uncertainty fades. Fair value post-deal closure is ₹1,200–1,500 (depending on integration speed). Current price of ₹1,788 implies best-case scenario is already baked in.

✓ Strengths

  • 17.8% ROCE — capital-efficient business model
  • 75% repeat orders — sticky revenue base
  • Global footprint in 70+ countries — diversification
  • Comminution circuit integration — durable moat post-Molycop
  • Zero promoter pledge — aligned incentives
  • Strong OCF of ₹195 cr — can service debt

✗ Weaknesses

  • 212-day working capital cycle — cash inefficient
  • Low ROE of 15.5% — leverage not optimal yet
  • P/E of 66.6x — valuation leaves no margin for error
  • Q3 margin compression (22% → 11% OPM) — execution risk visible
  • Equipment segment lumpy — 9M +34%, Q3 -13%

→ Opportunities

  • Molycop synergies — 1-2 years away if deal closes
  • Geographic expansion — Europe, LATAM, Australia pilots underway
  • Equipment scale — TMML/Molycop combo enables larger deals
  • Copper demand tailwind — 4% CAGR to 2030
  • Leverage reduction post-synergy — EV/EBITDA could contract to 15x

⚡ Threats

  • Antitrust delay or rejection — kills synergy story
  • Commodity cycle downturn — mining capex contracts sharply
  • Integration execution failures — two large global ops to mesh
  • Refinancing risk on Molycop debt — higher rates post-deal
  • WC pressure post-integration — cash bleed possible

Tega Industries is a company that made a bet. A big one.

The standalone consumables business is good. The Molycop acquisition is ambitious. The stock price (₹1,788) is pricing in most of the upside. The downside if execution stumbles is real (30-40%). The upside if everything works is also real (20-30%), but you’re already capturing most of it in the current price.

For conservative investors: wait for Molycop deal to close and synergies to start flowing (12+ months). Then re-evaluate at lower volatility. For aggressive investors: the risk/reward is borderline unattractive at current levels. You’re paying 66x P/E for a business that’s proven it can do 17-18% ROCE, not 25%+. That’s premium pricing for above-average, not premium execution.

The real catalyst is March 31, 2026 — deal closing day. If it closes, short-term volatility will spike. If it doesn’t, expect -15 to -25% downside. That’s your binary event in the next 45 days.

⚠️ EduInvesting Fair Value Range: ₹1,100 – ₹1,800. Current price ₹1,788 sits at the upper end of this range. This valuation assumes Molycop deal closes and synergy flows begin within 18 months. If the deal does not close or synergies are delayed, fair value could compress to ₹900–1,100. This analysis is strictly for educational purposes and does not constitute investment advice. Please consult a SEBI-registered investment advisor before making any financial decision.
error: Content is protected !!